DelveInsight’s ’Neuroendocrine Tumors (NETs)- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Neuroendocrine Tumors in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan


Study Period: 2017-2028

Neuroendocrine Tumors Disease Understanding
According to the Neuroendocrine Tumor Patient Foundation- “Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor)”.

Neuroendocrine Tumors Epidemiology
The Neuroendocrine Tumors (NETs) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Neuroendocrine Tumors are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Neuroendocrine Tumors Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases) scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Neuroendocrine Tumors (NETs) in 7 MM was found to be 453,191, in the year 2017.

Report scope

  • The report covers detailed overview of Neuroendocrine Tumors explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Neuroendocrine Tumors in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases in 7MM


Key strengths

  • 10 Year Forecast of Neuroendocrine Tumors epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of NETs
  • Prevalent Cases according to segmentation: total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases


Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population